Study Phase 2

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Trial Information

Generic NameRilematovirProduct NameN/ATherapeutic AreaAnti-Infectives for Systemic UseEnrollment72% Female51.4%% White83.3%
Product ClassAntivirals for Systemic UseSponsor Protocol Number53718678RSV2004Data PartnerJohnson & JohnsonCondition StudiedRespiratory Syncytial VirusesMean/Median Age (Years)53

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.